More News! 1 Nov 2017 Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro’s stock rose by 30% on Monday following an announcement of promising results from its relapsing-remitting multiple sclerosis drug, GNbAC1. After six months, the highest dose demonstrated an anti-inflammatory effect and seemed to stimulate […] November 1, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 27 Oct 2017 Lack of Permanent Academic Roles is Frightening News for PhD Students With Halloween around the corner, PhD students probably felt safe from any nasty surprises for a few more days but their careers in academia may have hit a snag. PhD students work very hard, but surely it is all worth it for the guarantee of a good job at the end of it all? A study […] October 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 17 Oct 2017 World’s First Molecular Computer Makes Data Storage 100 Times Smaller A team of French scientists has built the first molecular computer using polymers to store data, making each bit 100 times smaller than with current data storage. Just eight bytes encoding the word “Sequence” in ASCII code. A feat for the team of researchers that encoded and read the word using a synthetic polymer sequence. Their […] October 17, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 14 Oct 2017 Art and Biology Meet at Nonhuman Networks Exhibition in Berlin The exhibition Nonhuman Networks at Art Laboratory Berlin invites us to connect with other organisms and rethink our relationship with the environment. For those of us living in the Western world, our whole culture seems to revolve almost exclusively around ourselves. Despite having evolved within an ecosystem with a huge and fascinating diversity, we tend […] October 14, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 13 Oct 2017 German Biotech Gets €47M To Treat Painful Inflammatory Disease InflaRx has raised $55M (€47M) in a Series D fundraising in order to get its lead anti-inflammatory drug, IFX-1, through late-stage development. A year after its €31M Series C, InflaRx is closing a Series D round. The company has raised a total of $55M (€47M) from a team of US investors co-led by Bain Capital Life Sciences, […] October 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 10 Oct 2017 Update: Finnish Biotech to Raise £10M for Rare Lung Disease Drug Update (10/10/2017): Faron Pharmaceuticals’ fundraising has been October 10, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 2 Oct 2017 New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects Swedish Gesynta Pharma has signed an agreement with Orexo to acquire a drug candidate to treat inflammatory diseases with fewer side effects. Based in Uppsala, Orexo has built a solid pipeline since its foundation in 1995, including three products currently in the market. The company has now struck a deal for one of its early-stage programs, OX-MPI, focused on inflammation. BI1029539, the […] October 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Sep 2017 New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work on a new generation of antibody-drug conjugate (ADC) drugs. As part of the agreement, IONTAS will develop new antibodies against multiple undisclosed targets, on which Glythera will have the option […] September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 19 Sep 2017 Scottish Scientists Claim that the Genome Controls the Aging of the Brain Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […] September 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 18 Sep 2017 Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […] September 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 14 Sep 2017 New Dutch Spin Out will Treat Stroke with RNA Therapy ProQR has spun out Amylon Therapeutics, a company that will treat central nervous system disorders with a lead candidate based on RNA technology. Amylon Therapeutics, a brand new spin-out from RNA company ProQR, has announced its first seed investment round. The funds, of an undisclosed amount, will help the new company kick off the development of its drug candidates. Based in Leiden, Amylon […] September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 14 Sep 2017 Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance? Scientists in the UK and US have identified how in-fighting between bacteria could provide a new treatment for hospital-acquired infections. Clostridium difficile is a common cause of hospital-acquired infections, which kill almost 4,000 people in Europe each year. Scientists at the University of Sheffield, the University of Glasgow, and California-based biotech AvidBiotics Corp have discovered that C. difficile uses nanomolecular […] September 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email